The European Medicines Agency (EMA) has started a review into the screening of patients before they begin treatment with certain drugs. Most of the drugs in question are chemotherapies, and they ...

Reply to: “Give Patients the Choice to Test for DPD Deficiency Before Fluoropyrimidine Chemotherapy,” “Large-Scale DPD Testing Should Be More Than an Option,” and “A Big Problem With a Feasible ...

The European Medicines Agency (EMA) on Friday initiated a review of existing screening methods and their value in identifying patients at increased risk of severe side effects when taking medicines ...

Before patients with cancer begin treatment with intravenous fluorouracil and related drugs, they should be tested for lack of the enzyme dihydropyrimidine dehydrogenase (DPD), says an EU panel.

The fluoropyrimidine 5-fluorouracil (5-FU) and its prodrug capecitabine, are the cornerstone of treatment of numerous types of cancer. The use of fluoropyrimidines is associated with numerous side ...